Boxcman,Biocurex is not for sale.
Semi’s the word.
That brings us to the term ‘semi-exclusive’ within Tuesday’s release. Biocurex, for obvious reasons, is loath to grant exclusivity to any one company. Top-tier companies such as Abbott historically tend to want exclusivity. The fact that Abbott entered into a semi-exclusive arrangement, leaving Biocurex the right to enter into licensing arrangements with other companies, we believe, evidences the potential it sees in the technology and further enforces RECAF’s™ viability.